L-Polamidon

Levomethadone Hydrochloride, the active ingredient in L-Polamidon, is an opioid presented as an oral pharmaceutical product for systemic use. It is employed in the management of opioid dependence and for the relief of moderate to severe chronic pain in adult patients.

GNH USA supplies L-Polamidon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for cross‑border distribution. Customers benefit from reliable logistics, batch traceability, and responsive technical support throughout the supply chain.

Levomethadone Hydrochloride is employed within opioid‑related therapeutic pathways, chiefly for the treatment of opioid dependence and for providing analgesia in chronic pain conditions.

- Opioid dependence: reduces withdrawal symptoms and supports maintenance therapy. - Chronic pain: provides analgesic relief for moderate to severe persistent pain. - Detoxification: assists in supervised opioid detox programs to ease transition off opioids.

Levomethadone may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Constipation - Dizziness - Sedation

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation - Seizures - Severe allergic reactions

When prescribing levomethadone, clinicians should observe several safety precautions to minimize risk.

- Respiratory assessment: evaluate baseline breathing function and monitor for depression. - Cardiac monitoring: check QT interval and avoid use in patients with known prolongation. - Hepatic function: adjust dose or avoid in severe liver impairment. - Concomitant CNS depressants: use caution when combined with alcohol, benzodiazepines, or other opioids. - Discontinuation: taper gradually under medical supervision to prevent withdrawal. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Levomethadone interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid): - Other opioids: additive respiratory depression. - CNS depressants (e.g., benzodiazepines, barbiturates): heightened sedation and respiratory risk. - MAO inhibitors: risk of severe hypertension or serotonin syndrome. - QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics): increased cardiac arrhythmia risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise levomethadone levels. - Alcohol: enhances sedative effects. - Antidepressants (especially SSRIs): potential for increased sedation. - Antihistamines: may augment drowsiness.